NovoCure (NVCR) Interest Expenses (2014 - 2026)

NovoCure (NVCR) has reported Interest Expenses for 13 consecutive years, with $5.5 million the latest figure, recorded in Q2 2026.

• Quarterly Interest Expenses rose 93.13% year-over-year to $5.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $19.8 million (up 75.24% YoY) and the FY2025 annual result came in at $1.8 billion, up 12.0% from the prior year.
• Interest Expenses improved to $5.5 million in Q2 2026 per NVCR's latest filing, from $5.4 million in the prior quarter.
• Over the last five years, Interest Expenses for NVCR reached as high as $8.1 million in Q4 2022 and fell as low as $2000.0 in Q1 2024.
• A 5-year average of $3.2 million and a median of $2.8 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses sank 99.75% — and 2025, when it surged 139400.0%.
• Year by year, Interest Expenses stood at $8.1 million in 2022, then tumbled by 39.51% to $4.9 million in 2023, then tumbled by 47.72% to $2.6 million in 2024, then soared by 136.18% to $6.1 million in 2025, then declined by 9.94% to $5.5 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $5.5 million, $5.4 million, and $6.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.